Last reviewed · How we verify
Local Corticosteroid Therapy
Local corticosteroid therapy reduces inflammation and immune response at the site of application by suppressing inflammatory mediators and immune cell activity.
Local corticosteroid therapy reduces inflammation and immune response at the site of application by suppressing inflammatory mediators and immune cell activity. Used for Inflammatory skin conditions (e.g., eczema, psoriasis, dermatitis), Post-operative inflammation and edema, Joint and soft tissue inflammation.
At a glance
| Generic name | Local Corticosteroid Therapy |
|---|---|
| Sponsor | Spaulding Rehabilitation Hospital |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology, Rheumatology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids bind to glucocorticoid receptors in target tissues, inhibiting the production of pro-inflammatory cytokines, chemokines, and adhesion molecules. This localized anti-inflammatory effect reduces swelling, erythema, and pruritus while minimizing systemic exposure and adverse effects compared to systemic administration.
Approved indications
- Inflammatory skin conditions (e.g., eczema, psoriasis, dermatitis)
- Post-operative inflammation and edema
- Joint and soft tissue inflammation
Common side effects
- Skin atrophy
- Local irritation or burning
- Folliculitis
- Hypopigmentation
Key clinical trials
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo. (PHASE4)
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata (PHASE4)
- Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Local Corticosteroid Therapy CI brief — competitive landscape report
- Local Corticosteroid Therapy updates RSS · CI watch RSS
- Spaulding Rehabilitation Hospital portfolio CI